Review
Immunology
Haya Altawalah
Summary: The novel coronavirus, SARS-CoV-2, is the causative agent of COVID-19. The severity of the disease ranges from asymptomatic to critical, and it has been a global challenge since the first case in 2019, especially with the emergence of variants in 2021. Understanding immune response during COVID-19 and vaccination is crucial for managing the pandemic and optimizing vaccination strategies.
Article
Public, Environmental & Occupational Health
Mareen D. Rosenstein, Adriette W. de Visser, Leo G. Visser, Anna H. E. Roukens
Summary: Research shows that older travelers aged 60 and over remain seropositive 10 years after primary yellow fever vaccination, suggesting that a single dose of the vaccine can provide long-lasting immunity for at least a decade.
JOURNAL OF TRAVEL MEDICINE
(2021)
Article
Immunology
Riccardo De Santis, Giovanni Faggioni, Alessandra Amoroso, Andrea Ciammaruconi, Alice Pomponi, Maria Stella Lia, Donatella Amatore, Filippo Molinari, Giancarlo Petralito, Paola Stefanelli, Giovanni Rezza, Florigio Lista
Summary: According to the World Health Organization, one dose of yellow fever vaccine can provide lifelong protection in healthy adults. However, there is limited information available regarding the long-term persistence of neutralizing antibodies. Our study evaluated the persistence of neutralizing antibodies in a large group of military personnel who were vaccinated up to 47 years ago. The results showed that 99.1% of the participants had detectable neutralizing antibodies, with the highest levels observed in those vaccinated within 1 year. These findings confirm that neutralizing antibodies can persist for up to 47 years after a single dose of yellow fever vaccine.
Article
Virology
Mengmeng Jia, Xinming Wang, Wensheng Gong, Jingchuan Zhong, Zhiwei Leng, Lili Ren, Luzhao Feng, Li Guo, Lidong Gao, Xian Liang, Enfu Chen, Wenge Tang, Qiangru Huang, Qiao Zhang, Guangjiong Jiang, Shanlu Zhao, Zhu Liu, Yan Feng, Li Qi, Libing Ma, Tingxuan Huang, Yong Yue, Ju Wang, Binshan Jiang, Liuhui Xu, Jianwei Wang, Weizhong Yang, Chen Wang
Summary: This study evaluated the immune responses to inactivated COVID-19 vaccination in different groups (naive individuals, asymptomatically infected individuals, and recovered patients), and found that a single dose of vaccine is sufficient for recovered patients, and the second dose does not substantially increase antibody levels.
JOURNAL OF MEDICAL VIROLOGY
(2022)
Article
Virology
Marycelin M. Baba, Khalid M. Yahaya, Emmanuel M. Ezra, Musa Adamu, Bulama M. Kulloma, Mayomi Ikusemoran, John P. Momoh, Bamidele S. Oderinde
Summary: The study revealed that immunity against Yellow Fever in Nigeria is relatively high, but there is still a population at risk of epidemics due to lack of vaccination. It is crucial to target individuals aged 20 and above during mass vaccination campaigns to prevent recurring epidemics.
JOURNAL OF MEDICAL VIROLOGY
(2021)
Article
Rheumatology
Betina Soares dos Reis, Felipe Cintra Staub, Andrea Koishi, Camila Zanluca, Claudia Nunes Duarte dos Santos, Thelma L. Skare, Barbara Stadler Kahlow
Summary: The study found that fractionated dose of yellow fever vaccine is effective and safe in rheumatoid arthritis patients, with no clinical infection symptoms observed in the patients.
CLINICAL RHEUMATOLOGY
(2022)
Article
Immunology
Nadia Oreshkova, Sebenzile K. Myeni, Niraj Mishra, Irina C. Albulescu, Tim J. Dalebout, Eric J. Snijder, Peter J. Bredenbeek, Kai Dallmeier, Marjolein Kikkert
Summary: The study successfully generated a novel vaccine platform by inserting subunits from three different betacoronaviruses into the yellow fever virus 17D vaccine, which elicited good immune responses in mice. These YF17D replicon-based vaccines could be a promising and safe option for current and future emerging coronaviruses.
Article
Multidisciplinary Sciences
Young-Jun Park, Dora Pinto, Alexandra C. Walls, Zhuoming Liu, Anna De Marco, Fabio Benigni, Fabrizia Zatta, Chiara Silacci-Fregni, Jessica Bassi, Kaitlin R. Sprouse, Amin Addetia, John E. Bowen, Cameron Stewart, Martina Giurdanella, Christian Saliba, Barbara Guarino, Michael A. Schmid, Nicholas M. Franko, Jennifer K. Logue, Ha V. Dang, Kevin Hauser, Julia di Iulio, William Rivera, Gretja Schnell, Anushka Rajesh, Jiayi Zhou, Nisar Farhat, Hannah Kaiser, Martin Montiel-Ruiz, Julia Noack, Florian A. Lempp, Javier Janer, Rana Abdelnabi, Piet Maes, Paolo Ferrari, Alessandro Ceschi, Olivier Giannini, Guilherme Dias De Melo, Lauriane Kergoat, Herve Bourhy, Johan Neyts, Leah Soriaga, Lisa A. Purcell, Gyorgy Snell, Sean P. J. Whelan, Antonio Lanzavecchia, Herbert W. Virgin, Luca Piccoli, Helen Y. Chu, Matteo Samuele Pizzuto, Davide Corti, David Veesler
Summary: SARS-CoV-2 Omicron sublineages have spike mutations that allow them to evade antibodies from previous infection or vaccination. Hybrid immunity or booster shots can generate neutralizing antibodies against Omicron variants, and breakthrough infections lead to the production of neutralizing antibodies in the nasal mucosa. Antibodies derived from memory B cells or plasma cells of Omicron breakthrough cases show cross-reactivity with different receptor-binding domains, while primary Omicron infections elicit B cells with narrow specificity. A highly potent pan-variant-neutralizing antibody has been identified as a potential candidate for clinical development.
Review
Immunology
Jolynne Mokaya, Derick Kimathi, Teresa Lambe, George M. Warimwe
Summary: Yellow fever remains a global health threat, with efforts to eliminate it by vaccinating one billion people at risk by 2026. The current vaccine provides good protection, but production challenges limit its use, leading to exploration of alternative dosing strategies. Understanding immune responses to vaccination and exploring antibody characteristics and cell-mediated immunity are important for developing a comprehensive understanding of protective immunity.
Review
Microbiology
Ana Vazquez-Pagan, Stacey Schultz-Cherry
Summary: This article highlights the high risk of severe influenza for pregnant women, newborns, and infants under six months old, emphasizing the importance of vertically transferred immunity. It summarizes novel insights from recent studies and discusses the impact of maternal antibodies on early life immunity, stressing the need for continued research using pregnant animal models and including pregnant women in evaluating novel vaccine platforms.
Review
Microbiology
Katharina Roltgen, Scott D. Boyd
Summary: Human immune responses to SARS-CoV-2 have made significant progress in understanding the nature of antibody responses and their role in protecting against infection or modulating the severity of COVID-19, aiding in the development of effective vaccines. However, important questions remain unanswered regarding the duration and effectiveness of antibody responses, immunity differences between infection and vaccination, cellular basis for serological findings, and the potential impact of viral variants on current immunity.
CELL HOST & MICROBE
(2021)
Article
Immunology
Laise Rodrigues Reis, Ismael Artur da Costa-Rocha, Ana Carolina Campi-Azevedo, Vanessa Peruhype-Magalhaes, Jordana Grazziela Coelho-Dos-Reis, Christiane Costa-Pereira, Dayane Andriotti Otta, Larissa Chaves Freire, Sheila Maria Barbosa de Lima, Adriana de Souza Azevedo, Waleska Dias Schwarcz, Ana Paula Dinis Ano Bom, Andrea Marques Vieira da Silva, Alessandro Fonseca de Souza, Thalita da Matta de Castro, Clara Lucy de Vasconcellos Ferroco, Ana Maria Bispo de Filippis, Fernanda de Bruycker Nogueira, Akira Homma, Carla Magda Domingues, Eduardo Sergio Soares Sousa, Luiz Antonio Bastos Camacho, Maria de Lourdes de Souza Maia, Andrea Teixeira-Carvalho, Olindo Assis Martins-Filho
Summary: This study investigated the influence of pre-existing flavivirus immunity and age on the immunity provided by 17DD-YF vaccination. The results showed that there were differences in flavivirus seropositivity rates at baseline between children and adults. Pre-existing flavivirus seropositivity had an impact on the cellular immune response. Additionally, adults had higher levels of YF-neutralizing antibodies after primary vaccination compared to younger children, but antibody levels declined more rapidly in children. These findings suggest that age affects the duration of the cellular immune response following 17DD-YF vaccination.
Article
Microbiology
Wei Zhao, Weixin Chen, Juan Li, Meng Chen, Qin Li, Min Lv, ShanShan Zhou, Shuang Bai, Yali Wang, Lichi Zhang, Peng Zhang, Jian Wang, Qun Zheng, Jiang Wu
Summary: This study reported the long-term persistence of antibodies and cellular responses within 12 months after two doses of CoronaVac vaccine. The results showed that binding and neutralizing antibodies could be detected at 1 month after vaccination and remained detectable at significantly higher levels than baseline at 12 months. In addition, the study found that CoronaVac induced functional SARS-CoV-2-specific CD4(+) and CD8(+) memory T cells, which persisted up to 12 months after vaccination.
Article
Immunology
Ji Ma, Robbert Boudewijns, Lorena Sanchez-Felipe, Niraj Mishra, Thomas Vercruysse, Dieudonne Buh Kum, Hendrik Jan Thibaut, Johan Neyts, Kai Dallmeier
Summary: Research evaluated the immunogenicity and protective efficacy of the live-attenuated yellow fever 17D (YF17D) vaccine in various mouse models, highlighting the model-dependent differences in vaccine-induced protective immunity.
EMERGING MICROBES & INFECTIONS
(2021)
Article
Oncology
Lara Victoria Donhauser, Julia Veloso de Oliveira, Cordula Schick, Wenzel Manlik, Sabrina Styblova, Sarah Lutzenberger, Michael Aigner, Patrick Philipp, Sebastian Robert, Beate Gandorfer, Dirk Hempel, Louisa Hempel, Dietmar Zehn
Summary: The study analyzed the response to BioNTech/Pfizer's anti-SARS-CoV-2 mRNA vaccine in 237 oncology outpatients and found that patients should wait at least 6 months to 12 months after systemic therapy before receiving mRNA vaccination.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Immunology
Tom Hofland, Anne W. J. Martens, Jaco A. C. van Bruggen, Renate de Boer, Sjoerd Schetters, Ester B. M. Remmerswaal, Frederike J. Bemelman, Mark-David Levin, Adriaan D. Bins, Eric Eldering, Arnon P. Kater, Sanne H. Tonino
Summary: The study identified CXCR5(+)PD-1(+) CD8 T cells in human peripheral blood and LN, which could play a crucial role during PD-1 ICB, indicating their potential importance in human immune therapy.
EUROPEAN JOURNAL OF IMMUNOLOGY
(2021)
Article
Cell Biology
Carlos van der Putten, Ester B. M. Remmerswaal, Matty L. Terpstra, Nelly D. van der Bom, Jesper Kers, Ineke J. M. ten Berge, Suzanne E. Geerlings, Rene A. W. van Lier, Frederike J. Bemelman, Michiel C. van Aalderen
Summary: In this study, the researchers aimed to investigate the presence and function of T-RM cells in healthy and allograft kidney tissue by analyzing the phenotype and function of T cells through multichannel flow cytometry. The results showed that kidney tissue samples contained a significant number of CD8 and CD4 T cells that were more actively cycling, expressed specific markers CXCR3 and CXCR6, produced higher levels of IFN gamma, and displayed polyfunctionality compared to circulating T cells.
Article
Genetics & Heredity
Quinten R. Ducarmon, Elisabeth M. Terveer, Sam Nooij, Michelle N. Bloem, Karuna E. W. Vendrik, Monique A. A. Caljouw, Ingrid M. J. G. Sanders, Sofie M. van Dorp, Man C. Wong, Romy D. Zwittink, Ed J. Kuijper
Summary: Nursing home residents have higher rates of MDRO colonisation, with antibiotic use and hospital admittance being risk factors. The gut microbiota may play a role in resistance against MDROs.
Article
Infectious Diseases
Jacek Czepiel, Marcela Krutova, Assaf Mizrahi, Nagham Khanafer, David A. Enoch, Marta Patyi, Aleksander Deptula, Antonella Agodi, Xavier Nuvials, Hanna Pituch, Malgorzata Wojcik-Bugajska, Iwona Filipczak-Bryniarska, Bartosz Brzozowski, Marcin Krzanowski, Katarzyna Konturek, Marcin Fedewicz, Mateusz Michalak, Lorra Monpierre, Philippe Vanhems, Theodore Gouliouris, Artur Jurczyszyn, Sarah Goldman-Mazur, Dorota Wultanska, Ed J. Kuijper, Jan Skupien, Grazyna Biesiada, Aleksander Garlicki
Summary: This study aimed to describe the clinical presentation, treatment, outcome, and factors associated with mortality in Clostridioides difficile infection (CDI) over a 90-day period. Older age, inadequate CDI therapy, cachexia, malignancy, Charlson Index, long-term care, elevated white blood cell count (WBC), C-reactive protein (CRP), bacteraemia, complications, and cognitive impairment were independently related with death during CDI. Additionally, factors such as older age, higher levels of WBC, neutrophil, CRP or creatinine, the presence of malignancy, cognitive impairment, and complications were strongly correlated with a shorter time from CDI diagnosis to death.
Article
Hematology
Hannah M. Garcia Garrido, Sabine Haggenburg, Marieke C. E. Schoordijk, Ellen Meijer, Michael W. T. Tanck, Mette D. Hazenberg, Caroline E. Rutten, Godelieve J. de Bree, Erfan Nur, Bob Meek, Martin P. Grobusch, Abraham Goorhuis
Summary: The immunogenicity of a 5-dose pneumococcal vaccination schedule was investigated in adult allo-HSCT recipients with and without immunosuppressive therapy. The study showed that immunosuppressive therapy resulted in a poor response to the vaccine, particularly for the PPSV23 serotypes. Further research on vaccination strategies with higher-valent T-cell-dependent pneumococcal vaccines is needed.
AMERICAN JOURNAL OF HEMATOLOGY
(2022)
Review
Gastroenterology & Hepatology
Manu P. Bilsen, Merel M. C. Lambregts, Joffrey van Prehn, Ed J. Kuijper
Summary: Recent studies have shown some effectiveness of fecal microbiota transplantation (FMT) for decolonization of multidrug-resistant organisms (MDRO), but questions remain regarding its true efficacy, optimal route of administration, role of antibiotics pre and post-FMT, and efficacy in different patient populations. Further research is needed to explore the observed decrease in MDRO infections post-FMT.
CURRENT OPINION IN GASTROENTEROLOGY
(2022)
Article
Medicine, General & Internal
Roos S. G. Sablerolles, Wim J. R. Rietdijk, Abraham Goorhuis, Douwe F. Postma, Leo G. Visser, Daryl Geers, Katharina S. Schmitz, Hannah M. Garcia Garrido, Marion P. G. Koopmans, Virgil A. S. H. Dalm, Neeltje A. Kootstra, Anke L. W. Huckriede, Melvin Lafeber, Debbie van Baarle, Corine H. GeurtsvanKessel, Rory D. de Vries, P. Hugo M. van der Kuy
Summary: This study investigated the immunogenicity and reactogenicity of a homologous or heterologous booster in healthcare workers who had received a single-shot Ad26.COV2.S vaccine. The results showed that booster vaccinations increased the levels of S-specific binding antibodies, neutralizing antibodies, and T-cell responses compared to a single Ad26.COV2.S vaccination. Boosters containing mRNA-based vaccines induced significantly higher levels of binding antibodies than homologous boosters. The mRNA-1273 booster was the most immunogenic but had higher reactogenicity compared to the BNT162b2 and Ad26.COV2.S boosters. Local and systemic reactions were generally mild to moderate in the first 2 days after booster administration.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Review
Public, Environmental & Occupational Health
Cornelis Adrianus De Pijper, Jenny Lea Schnyder, Cornelis Stijnis, Abraham Goorhuis, Martin Peter Grobusch
Summary: Severe thrombocytopenia is a rare but life-threatening complication of ZVI, with immune-induced thrombocytopenia as the main pathophysiological mechanism. Further research is needed to determine the optimal treatment strategy for this complication due to a lack of cases.
TRAVEL MEDICINE AND INFECTIOUS DISEASE
(2022)
Article
Hematology
Sabine Haggenburg, Birgit Lissenberg-Witte, Rob S. van Binnendijk, Gerco den Hartog, Michel S. Bhoekhan, Nienke J. E. Haverkate, Dennis M. de Rooij, Johan van Meerloo, Jacqueline Cloos, Neeltje A. Kootstra, Dorine Wouters, Suzanne S. Weijers, Ester M. M. van Leeuwen, Hetty J. Bontkes, Saida Tonouh-Aajoud, Mirjam H. M. Heemskerk, Rogier W. Sanders, Elianne Roelandse-Koop, Quincy Hofsink, Kazimierz Groen, Lucia Cetinel, Louis Schellekens, Yvonne M. den Hartog, Belle Toussaint, Iris M. J. Kant, Thecla Graas, Emma de Pater, Willem A. Dik, Marije D. Engel, Cheyenne R. N. Pierie, Suzanne R. Janssen, Edith van Dijkman, Meliawati Poniman, Judith A. Burger, Joey H. Bouhuijs, Gaby Smits, Nynke Y. Rots, Sonja Zweegman, Arnon P. Kater, Tom van Meerten, Pim G. N. J. Mutsaers, Jaap A. van Doesum, Annoek E. C. Broers, Marit J. van Gils, Abraham Goorhuis, Caroline E. Rutten, Mette D. Hazenberg, Inger S. Nijhof
Summary: Vaccination guidelines for hematological patients are typically conservative. However, this study shows that most patients, even those with compromised immune systems, can develop sufficient antibody concentrations after receiving the Moderna vaccine. However, certain treatments may affect the vaccine's efficacy.
Article
Infectious Diseases
Daan W. Notermans, Annelot F. Schoffelen, Fabian Landman, Cornelia C. H. Wielders, Sandra Witteveen, Varisha A. Ganesh, Marga Van Santen-Verheuvel, Sabine C. de Greeff, Ed J. Kuijper, Antoni P. A. Hendrickx
Summary: Urine-associated Escherichia coli ST38 producing OXA-244 harboring putative uropathogenicity factors emerged in the Netherlands.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2022)
Article
Microbiology
Ishani Wickramage, Zhong Peng, Soumyadeep Chakraborty, Celine Harmanus, Ed J. Kuijper, Sally Alrabaa, Wiep Klaas Smits, Xingmin Sun
Summary: Clostridioides difficile has a complex relationship with antibiotics, as they can both increase the risk of infection and be the primary treatment for C. difficile infection (CDI). This study identified two clinical isolates of C. difficile with elevated resistance to vancomycin and rifaximin, as well as mutations related to resistance. The findings highlight the importance of surveillance in understanding antibiotic resistance and developing effective treatment strategies.
MICROBIOLOGY SPECTRUM
(2023)
Article
Microbiology
P. M. C. Klein Klouwenberg, W. van der Kuil, A. J. van Griethuysen, M. Hendriks, E. J. Kuijper, D. W. Notermans, A. F. Schoffelen, ISIS AR Study Grp
Summary: Using data from the Dutch national surveillance system for antimicrobial resistance, this study found discrepancies in minimum inhibitory concentrations of aminoglycosides measured by the automated testing systems VITEK2 and Phoenix. The Phoenix system showed higher MICs and an annual increase in resistance for certain species. These findings have implications for the clinical treatment of sepsis patients.
MICROBIOLOGY SPECTRUM
(2023)
Article
Health Care Sciences & Services
Karuna E. W. Vendrik, Amoe Baktash, Jelle J. Goeman, Celine Harmanus, Daan W. Notermans, Sabine C. de Greeff, Ed J. Kuijper
Summary: This study found a higher proportion of severe CDI cases during the second wave of COVID-19, which was partially caused by delayed diagnostics possibly due to decreased patient visits or restricted hospital referral.
LANCET REGIONAL HEALTH-EUROPE
(2022)
Article
Health Care Sciences & Services
Martin P. Grobusch, Leisa Weld, Abraham Goorhuis, Davidson H. Hamer, Mirjam Schunk, Sabine Jordan, Frank P. Mockenhaupt, Francois Chappuis, Hilmir Asgeirsson, Eric Caumes, Mogens Jensenius, Perry J. J. van Genderen, Francesco Castelli, Rogelio Lopez-Velez, Vanessa Field, Emmanuel Bottieau, Israel Molina, Christophe Rapp, Marta Diaz Menendez, Effrossyni Gkrania-Klotsas, Carsten S. Larsen, Denis Malvy, David Lalloo, Federico Gobbi, Simin A. Florescu, Philippe Gautret, Patricia Schlagenhauf
Summary: The study evaluated travel-related illness encountered at EuroTravNet clinics between 1998 and 2018, finding an increase in ill travellers over the years. Despite this, regions of exposure remained stable. Diseases like falciparum malaria, rabies, and influenza showed varying trends over the years.
LANCET REGIONAL HEALTH-EUROPE
(2021)